您是记者吗?

了解 ALK

如有任何疑问,请直接联系 ALK 总部或任何全球办事处的媒体关系部。

The press releases in this press room contains information that is of general news value for the press, and available for journalists or media with a view to journalistic assessment and preparation before publication.

News

  • Post date
    06/15/2026
    EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis
  • Post date
    06/11/2026
    Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap
  • Post date
    06/04/2026
    ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026
  • Post date
    06/01/2026
    Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
  • Post date
    05/29/2026
    ALK to present at the Jefferies Global Healthcare Conference in New York
  • Post date
    05/04/2026
    ALK upgrades its full-year outlook
  • Post date
    05/04/2026
    Three-month interim report (Q1) 2026 (unaudited)
  • Post date
    04/28/2026
    Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026
  • Post date
    04/20/2026
    ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy

媒体关系

投资者关系

Per Plotnikof

企业传播、

投资者关系和战略规划

副总裁

电话:+45 2261 2525

电子邮件:PPIDK@alk.net

 

媒体关系

Jeppe Ilkjær

企业传播

媒体关系经理

电话:+45 3050 2014

电子邮件:Jeppe.Ilkjaer@alk.net

欢迎记者朋友随时联系 ALK 的媒体关系团队。
Steen Riisgaard, CEO
Production facilities, Hørsholm
Image
alk_produktion6_0
Production facilities, Hørsholm
Image
alk_produktion3_1
Production facilities, Hørsholm
Image
alk_produktion5
Production facilities, Hørsholm
Image
Family_website_0
ALK HQ, Hørsholm
Last updated: 2016.11.14